SAN FRANCISCO, May 18, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), being held June 3-7, 2011 in Chicago, Illinois. The data presentations at ASCO 2011 will highlight the anti-tumor activity of NKTR-102 in patients with metastatic breast cancer and platinum-resistant ovarian cancer. In addition, a separate presentation will be made on the population pharmacokinetics for NKTR-102.
"The NKTR-102 clinical data we will report at ASCO continue to support the robust clinical benefit and significant anti-tumor activity we have observed to date in our clinical studies with this promising anti-cancer agent," said Lorianne Masuoka, MD, Senior Vice President and Chief Medical Officer of Nektar. "These findings strongly support our continued development of NKTR-102 in multiple tumor settings."
Details for the poster discussion session and general poster presentations are below and the full abstracts are now available on the ASCO website at http://www.asco.org. NKTR-102 Data Presentations at ASCO 2011:
Anti-tumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC).Abstract #1034, Poster Board #24Poster Discussion Session: Breast Cancer - Triple-negative/Cytotoxics/Local Therapy Session Date and Time: Saturday, June 4, 2011, 2:00 PM – 6:00 PM, Central TimeLocation: E450b
The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal do
|SOURCE Nektar Therapeutics|
Copyright©2010 PR Newswire.
All rights reserved